Emergent BioSolutions lowers revenue guidance amid uncertainty over government’s vaccine purchases

Emergent BioSolutions Inc. has lowered its revenue guidance for the year, citing uncertain timing as to when the U.S. government might exercise its next option under an existing contract to buy more doses of a smallpox vaccine. The Gaithersburg company said this week it now expects revenue to fall within a range of $1.05 billion and $1.1 billion in revenue for 2022, after previously projecting to hit $1.15 billion to $1.25 billion.